Pricing
The same price whether the answer is yes or no.
Traditional feasibility studies run $20,000 to $50,000 and take six to twelve weeks. Many are also free, which is the more interesting number: a free study is paid for by the formation work, the management contract, or the commission that follows if the answer is yes.
We charge for the analysis and nothing else. No formation fee, no management contract, no commission, no office in any domicile. That is why the platform is able to return “do not proceed” without it costing us anything.
Single feasibility study
One complete feasibility analysis: actuarial projection, simulated funding range, domicile comparison, five-year pro formas, and a board-ready report.
Best for. A company testing the question once, or a CFO who wants an independent read alongside a broker's proposal.
- Chain-ladder and Bornhuetter-Ferguson projections, shown side by side
- Monte Carlo simulation at 10,000 iterations, seeded and reproducible
- Premium funding range at expected, 75th, 90th, and 95th percentiles
- Domicile scoring across all ten domiciles with adjustable weights
- IRC 831(b) diagnostics with the regulatory as-of date on every output
- Five-year pro formas under base, adverse, and severe-adverse scenarios
- Board-ready report, exportable
- Full audit vault for the study, retained and hash-verified
- A signed actuarial opinion — we are a modeling platform, not a credentialed signature
Nothing is charged until the analysis has run and you have seen the verdict.
Platform license
Unlimited studies for a year. Re-run as loss data matures, test alternative retentions, and compare structures without paying per analysis.
Best for. Brokers, CPAs, and risk advisers running the question across a book of clients — and companies that want to re-test annually as their loss history develops.
- Everything in the single study, without a per-study fee
- Unlimited studies and unlimited re-runs
- Versioned results — every re-run is retained, never overwritten
- Side-by-side comparison of study versions as data matures
- Audit vault across the whole portfolio
A purchase is tied to an account so your studies and receipts stay together.
PCC network membership
Access to a protected cell structure for companies too small to justify a standalone captive, with statutory cell segregation and credibility-weighted premium allocation.
Best for. Mid-market companies whose premium volume does not yet support $250,000 of dedicated capital and $50,000-$150,000 of annual standalone operating cost.
- Everything in the platform license
- Protected cell placement analysis and indicative allocation
- Credibility-weighted premium allocation across participating cells
- Statutory cross-liability segregation between cells, explained in full
- Cell-level pro formas and capital requirements
A purchase is tied to an account so your studies and receipts stay together.
What you are not buying
Being clear about the boundary.
Not a signed actuarial opinion. Most domiciles require a feasibility study signed by a qualified actuary as part of the licence application. This platform does not provide that signature. It uses the same methods, shows all of its working, and is designed to inform and accelerate that engagement — not to replace it.
Not legal or tax advice. The 831(b) diagnostics are deliberately conservative and cite their sources, but a micro-captive should be reviewed by tax counsel before formation, not after.
Not captive management. We do not administer captives, and we do not refer you to a manager who pays us. If we did, the independence claim on the front page would be worthless.
Questions
Not sure which one you need?
If you are testing the question once, take the single study. If you advise clients or expect to re-run as your loss history matures, the platform license pays for itself at the second study.